Fate Therapeutics Inc Asset Turnover Ratio (FATE), as of third quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Fate Therapeutics Inc   (NASDAQ: FATE)
 

Fate Therapeutics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

According to the latest Balance sheet Sep 30 2026, Fate Therapeutics Inc has not recorded any assets.
Visit Fate Therapeutics Inc Balance sheet

Within sector 65 more businesses have achieved higher asset turnover ratio. While ranking the asset turnover ratio, among all other companies, it is fair to say, that the company's position has deteriorated in the Third Quarter 2026 compared to the preceding quarter from 3651 to 3815.

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FATE Asset Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Asset Change -30.74 % 2.65 % -28.53 % -27.5 % -27.1 %
Y / Y Revenue Change - 9.18 % -20.26 % -26.4 % -43.36 %
Asset Turnover Ratio (TTM) - 0.02 0.02 0.02 0.02
FATE's Total Ranking # 3815 # 3651 # 2117 # 2294 #
Seq. Asset Change -37.54 % 33.89 % -11.08 % -6.87 % -7.43 %
Seq. Revenue Change - 60.28 % -5.11 % -21.37 % -8.7 %



Asset Turnover Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 66
Healthcare Sector # 537
Overall Market # 3815

Asset Turnover Ratio Statistics
High Average Low
0.19 0.06 0.01
(Mar 31 2023)   (Mar 31 2024)




FATE Company Profile • Back to FATE Efficiency Comparisons • Compare FATE Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Sep 30 2026 Assets at quarter ending Sep 30 2026
Seer Inc   0.05 $ 14.248  Millions$ 266.663  Millions
Recursion Pharmaceuticals Inc   0.05 $ 68.232  Millions$ 1,312.008  Millions
Abcellera Biologics Inc   0.05 $ 67.858  Millions$ 1,367.875  Millions
Lenz Therapeutics Inc   0.05 $ 12.359  Millions$ 256.189  Millions
Co diagnostics Inc   0.05 $ 0.859  Millions$ 18.906  Millions
Cytomx Therapeutics Inc   0.04 $ 14.027  Millions$ 314.207  Millions
Metagenomi Therapeutics Inc   0.04 $ 7.086  Millions$ 187.286  Millions
Aclaris Therapeutics Inc   0.03 $ 6.401  Millions$ 188.758  Millions
Ideaya Biosciences Inc   0.03 $ 36.535  Millions$ 1,166.348  Millions
Dbv Technologies S a   0.02 $ 3.844  Millions$ 234.675  Millions
Anteris Technologies Global Corp   0.01 $ 2.332  Millions$ 227.598  Millions
Crispr Therapeutics Ag  0.01 $ 25.172  Millions$ 2,549.561  Millions
Upstream Bio Inc   0.01 $ 2.870  Millions$ 299.747  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.